PMGC Holdings (ELAB) Change in Receivables (2022 - 2026)
PMGC Holdings (ELAB) posted Change in Receivables of -$120049.0 for Q1 2026, down 739.14% sequentially from $18783.0 in Q4 2025, and down 256.6% YoY from $76660.0 in Q1 2025.
PMGC Holdings (ELAB) Change in Receivables (2022 - 2026) Analysis & Trends
PMGC Holdings has reported Change in Receivables for 5 years, with the latest figure at -$120049.0 in Q1 2026.
- Quarterly Change in Receivables fell 256.6% year-over-year to -$120049.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$96115.0 (down 234.41% YoY) and the FY2025 annual result came in at $100594.0, up 675.65% from the prior year.
- Change in Receivables retreated to -$120049.0 in Q1 2026 per ELAB's latest filing, from $18783.0 in the prior quarter.
- Over five years, Change in Receivables peaked at $76660.0 in Q1 2025 and troughed at -$13.8 million in Q4 2022.
- A 5-year average of -$984480.1 and a median of $8405.5 in 2024 frame the typical range for Change in Receivables.
- The widest YoY moves for Change in Receivables: up 323.09% in 2025, down 1632.57% in 2025.
- Over 5 years, Change in Receivables stood at -$13.8 million in 2022, then soared by 100.2% to $27725.0 in 2023, then dropped by 23.41% to $21235.0 in 2024, then retreated by 11.55% to $18783.0 in 2025, then slumped by 739.14% to -$120049.0 in 2026.
- According to Business Quant data, Change in Receivables over the past three periods registered -$120049.0, $18783.0, and -$22662.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | PMGC Holdings | 31.22 Mn | 12.43 Mn | 385,691.00 | -409,909.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -120,049.00 |
| Mar 31, 2026 | -120,049.00 |
| Dec 31, 2025 | 18,783.00 |
| Dec 31, 2025 | 18,783.00 |
| Sep 30, 2025 | -22,662.00 |
| Sep 30, 2025 | -22,662.00 |
| Jun 30, 2025 | 27,813.00 |
| Jun 30, 2025 | 27,813.00 |
| Mar 31, 2025 | 76,660.00 |
| Mar 31, 2025 | 76,660.00 |
| Dec 31, 2024 | 21,235.00 |
| Dec 31, 2024 | 21,235.00 |
| Sep 30, 2024 | -1,308.00 |
| Sep 30, 2024 | -1,308.00 |
| Jun 30, 2024 | -25,077.00 |
| Jun 30, 2024 | -25,077.00 |
| Mar 31, 2024 | 18,119.00 |
| Mar 31, 2024 | 18,119.00 |
| Dec 31, 2023 | 27,725.00 |
| Dec 31, 2023 | 27,725.00 |